glucose levels Archives - Amazing Health Advances

Study On Time Restricted Eating Reveals Limiting Food Intake to Daytime Shows Promising Beneficial Metabolic Effects in Adults With Type 2 Diabetes

AHA Publisher — Wed, 27 Jul 2022 07:00:49 +0000

Diabetologia via Newswise – A new study published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]) finds that following a time-restricted eating (TRE) protocol which limits food intake to a max 10-hour time window shows promising beneficial metabolic effects in adults with type 2 diabetes (T2D). The research was conducted by Prof Patrick Schrauwen, Charlotte Andriessen and colleagues at NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, the Netherlands. Our modern 24-hour society is characterised by endless food availability and disrupted day-night rhythm brought on by irregular sleep-activity patterns and frequent exposure to artificial light sources. In Western nations, people also tend to spread their daily food intake over a minimum of 14 hours, which is likely to result in the absence of a true, nocturnal fasted state. These factors all contribute to the development of T2D which has become one of the most common metabolic diseases globally, estimated by the World Health Organization to cause more than 1.5 million deaths per year. TRE is a novel strategy for improving metabolic health and is intended to counteract the detrimental effects of eating throughout the day by limiting the duration of food intake (typically 12 h or less) and restore the cycle of daytime eating and prolonged fasting during the evening and night. Previous studies show that TRE leads to promising metabolic changes in people with overweight or obesity, including increased fat burning, decreased blood sugar levels and improved insulin sensitivity; but these effects have not been studied in detail. Moreover, while these results are promising, these studies used extremely short eating time windows (6-8 h) and highly controlled study settings, making such protocols difficult to implement in daily life. TRE is sometimes accompanied by unintended weight loss which would be expected to increase metabolic health, but such improvements have also been reported in the absence of weight loss, indicating that additional mechanisms are involved in how restricted eating influences metabolism. Individuals with impaired metabolic health experience alterations in the rhythms of metabolic processes compared to healthy, lean individuals and the authors hypothesise that a disturbed fed-fasting cycle contributes to these impairments in metabolic rhythms. They suggest that by restricting food intake to daytime only and extending the length of the nocturnal fast may have beneficial effects on metabolic health. The researchers recruited 14 individuals with T2D for the study, aged between 50 and 75 years (7 male, 7 female, average age 67.5 years) and body mass index (BMI) ≥25 kg/m2. The study consisted of two 3-week intervention periods: TRE and control (CON), separated by a wash-out period of at least 4 weeks. At the start of each intervention, participants had their body weight measured and were fitted with a continuous glucose monitoring (CGM) device which measured their blood sugar level every 15 minutes. They were instructed to keep to their normal sleep patterns and physical activity, and to maintain a stable weight. A food and sleep diary completed during the first intervention was used to ensure that diet during the second period was similar in both quantity and quality. During TRE participants were instructed to consume their normal diet within a 10-hour window during the daytime, and to complete their food intake no later than 1800H. Outside this time window they were permitted to drink water, plain tea, or black coffee, and zero-calorie soft drinks were also allowed during the evening if consumed in moderation. During CON volunteers were only required to spread their normal food intake over at least 14 hours, with no other restrictions. The eating window for TRE averaged 9.1 h compared to 13.4 h in CON, while sleep-wake patterns were similar in each case with mean sleep durations of 8.1 h and 8.0 h, respectively. Mean body mass was comparable at the start of both TRE and CON and although volunteers were instructed to remain weight stable, a small but statistically significant weight loss occurred in response to TRE but not CON. TRE was found to decrease 24-hour glucose levels, primarily as a result of lower nocturnal blood sugar, and the average time spent with blood glucose in the normal range increased to 15.1 hours versus 12.2 hours during the CON phase. Morning fasting glucose was consistently lower among the TRE group than those on the control diet, which may be the result of lasting changes in nocturnal glucose control. Time spent in hypoglycaemia (low blood sugar) was not significantly increased by TRE and no serious adverse effects were reported resulting from the protocol, demonstrating that an eating window of approximately 10 h is a safe and effective lifestyle intervention for adults with T2D. Approximately half-way through each intervention, liver glycogen levels were assessed in the morning following the 10 h or 14 h night-time fast period, and were measured again at the end of each study period after an 11 h fast for both TRE and CON. In both cases, liver glycogen did not differ significantly between TRE and CON and an analysis of liver fats showed no difference in their quantity or composition between interventions. Unlike a previous study into TRE, this one did not show that the protocol had any effect on insulin sensitivity, however the earlier research had used a much shorter 6 h food intake window with the last meal being consumed at 15:00 h. This resulted in a longer fasting period which may have been more effective but was felt to be unrealistic to incorporate into the lifestyle of most adults with T2D. The team advise: “Future studies will be needed to reveal whether the duration of the fasting period is indeed crucial in determining positive effects on insulin sensitivity.” The authors say: “Mechanisms underlying the improvement in glucose regulation upon TRE remain unclear. Our results show that TRE did not improve peripheral and liver insulin sensitivity, skeletal muscle mitochondrial function, energy metabolism or liver fat content, all of which are known to be affected in T2D.” They propose that the mechanisms involved in the effects and their implications should be investigated further, with particular focus on studying nocturnal glucose metabolism in more detail. Limitations of this research include its relatively short duration and that some but not all participants were on glucose-lowering medication which may have caused TRE to have less effect. Despite this, a 3-week intervention period has been found to be long enough to affect the variables being analysed, and the authors highlight that only recruiting volunteers who were not on medication would reduce the study’s relevance to the general T2D population. The authors conclude: “A daytime 10 h TRE regimen for 3 weeks decreases glucose levels and prolongs the time spent in the normal blood sugar range in adults with T2D as compared with spreading daily food intake over at least 14 h. These data highlight the potential benefit of TRE in T2D” They also suggest: “Since our TRE protocol was feasible and safe, and resulted in improved 24 h glucose levels, it would be interesting to examine the impact of 10 h TRE on glucose regulation and insulin sensitivity in type 2 diabetes in the long term to address the clinical relevance of TRE.” To read the original article click here.

The post Study On Time Restricted Eating Reveals Limiting Food Intake to Daytime Shows Promising Beneficial Metabolic Effects in Adults With Type 2 Diabetes appeared first on Amazing Health Advances.

Antacids May Improve Blood Sugar Control in People with Diabetes

AHA Publisher — Wed, 30 Jun 2021 07:00:36 +0000

Endocrine Society viaNewswise– WASHINGTON—Antacids improved blood sugar control in people with diabetes but had no effect on reducing the risk of diabetes in the general population, according to a new meta-analysis published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Type 2 diabetes is a global public health concern affecting almost 10 percent of people worldwide. Doctors may prescribe diet and lifestyle changes, diabetes medications, or insulin to help people with diabetes better manage their blood sugar, but recent data points to common over the counter antacid medicines as another way to improve glucose levels. “Our research demonstrated that prescribing antacids as an add-on to standard care was superior to standard therapy in decreasing hemoglobin A1c (HbA1c) levels and fasting blood sugar in people with diabetes,” said study author Carol Chiung-Hui Peng, M.D., of the University of Maryland Medical Center Midtown Campus in Baltimore, Md. “For people without diabetes, taking antacids did not significantly alter their risk of developing the disease,” said study author, Huei-Kai Huang, M.D., of the Hualien Tzu Chi Hospital in Hualien, Taiwan. The researchers performed a meta-analysis on the effects of proton pump inhibitors (PPIs)—a commonly used type of antacid medication—on blood sugar levels in people with diabetes and whether these medications could prevent the new onset of diabetes in the general population. The analysis included seven studies (342 participants) for glycemic control and 5 studies (244, 439 participants) for risk of incident diabetes. The researchers found antacids can reduce HbA1c levels by 0.36% in people with diabetes and lower fasting blood sugar by 10 mg/dl based on the results from seven clinical trials. For those without diabetes, the results of the five studies showed that antacids had no effect on reducing the risk of developing diabetes. “People with diabetes should be aware that these commonly used antacid medications may improve their blood sugar control, and providers could consider this glucose-lowering effect when prescribing these medications to their patients,” said study author Kashif Munir, M.D., associate professor in the division of endocrinology, diabetes and nutrition at the University of Maryland School of Medicine in Baltimore, Md. To read the original article click here.

The post Antacids May Improve Blood Sugar Control in People with Diabetes appeared first on Amazing Health Advances.

Hospitalized COVID-19 Patients Fare Worse When They Have High Blood Sugar

AHA Publisher — Thu, 01 Apr 2021 07:00:16 +0000

Endocrine Society via Newswise – Patients hospitalized with COVID-19 have worse outcomes if they have high blood sugar, or hyperglycemia, regardless of whether they have diabetes, a new study finds. The researchers will present their results, of the first known study of the impact of hyperglycemia on a largely Black patient population with the novel coronavirus, at ENDO 2021, the Endocrine Society’s annual meeting. The investigators found that patients with COVID-19 who had hyperglycemia on admission to the hospital were more likely than those with normal glucose (sugar) to require a breathing machine or admission to the intensive care unit (ICU). These patients also were reportedly likelier to have kidney injury and to die in the hospital. “COVID-19 patients presenting to the hospital with hyperglycemia require closer observation, as they are likely to require more aggressive therapies,” said the study’s lead investigator, Samara Skwiersky, M.D., M.P.H., an internal medicine resident physician at the State University of New York (SUNY) Downstate Medical Center in Brooklyn, N.Y. Although a few prior studies have identified hyperglycemia or diabetes as an independent risk factor for worse COVID-19 outcomes, Skwiersky said they did not take place in a predominantly Black population. The virus has disproportionately affected Black people, including higher rates of hospitalization and death than in white people, she noted. Their study included 708 adults with COVID-19 admitted to SUNY Downstate Medical Center, 89 percent of whom were Black. About half were men, and 54 percent of patients had a history of either type 1 or type 2 diabetes on admission. The researchers studied patient outcomes by the presence or absence of diabetes and by their blood glucose values on admission. Because guidelines recommend that hospitalized patients with diabetes maintain blood glucose levels between 140 and 180 milligrams per deciliter (mg/dL), the investigators divided patients into groups by glucose levels less than 140 and less than 180 mg/dL. Patients with diabetes whose blood glucose values on admission exceeded 140 mg/dL had a 2.4-fold increased odds of ICU admission and intubation—needing a breathing machine—versus those whose glucose levels were lower, the researchers reported. Furthermore, patients with diabetes whose admission glucose levels were higher than 180 mg/dL had an approximately twofold increased odds of in-hospital death, their data showed. However, Skwiersky said the odds of death also were increased twofold for patients who did not have diabetes and whose glucose values exceeded 140 mg/dL. Additionally, these patients had a 3.5-fold raised odds of ICU admission and a 2.3-fold higher odds of intubation and of experiencing acute kidney injury. According to Skwiersky, patients without diabetes whose blood glucose levels topped 180 mg/dL had a fourfold greater death risk, a nearly threefold increased odds of ICU admission, and a 2.7-fold higher odds of intubation. “The results from our study,” she said, “reiterate the importance of regularly monitoring blood glucose in patients hospitalized with COVID-19, even without a prior diagnosis of diabetes.” It is unclear whether hyperglycemia is the result of or a cause of more severe COVID-19 illness, Skwiersky stated. Still, she said their results suggest the need for intensive glucose control in hospitalized COVID-19 patients with high blood sugar. This is consistent with the current Endocrine Society guidelines, which recommend that all patients with blood glucose above 140 mg/dL be monitored with point–of–care glucose testing and treated with appropriate therapies. “More frequent glucose monitoring and treatment with insulin therapy to a target glucose value less than 140 mg/dL could improve outcomes in these patients,” Skwiersky said. To read the original article click here.

The post Hospitalized COVID-19 Patients Fare Worse When They Have High Blood Sugar appeared first on Amazing Health Advances.